Dr. Reddy’s Laboratories Ltd ADR Cash Flow Conversion Efficiency
Dr. Reddy’s Laboratories Ltd ADR cash flow conversion efficiency. Based on the latest financial reports, Dr. Reddy’s Laboratories Ltd ADR (RDY) has a cash flow conversion efficiency ratio of 0.029x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($10.91 Billion) by net assets ($375.76 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Dr. Reddy’s Laboratories Ltd ADR (2000–2025)
Cash flow conversion efficiency of Dr. Reddy’s Laboratories Ltd ADR from 2000 to 2025. This chart illustrates how Dr. Reddy’s Laboratories Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RDY live share price for real-time trading data and today's change.
Dr. Reddy’s Laboratories Ltd ADR Cash Flow Conversion Ratio Explained
Dr. Reddy’s Laboratories Ltd ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Dr. Reddy’s Laboratories Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dr. Reddy’s Laboratories Ltd ADR ranked by their cash flow conversion efficiency. Also see Dr. Reddy’s Laboratories Ltd ADR market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Deckers Outdoor Corporation
NYSE:DECK
|
0.021x |
|
ZTO Express (Cayman) Inc
NYSE:ZTO
|
0.044x |
|
JAMES HARDIE INDUST.ADR/1
F:JHA0
|
N/A |
|
Eurofins Scientific SE
F:ESF0
|
0.073x |
|
Zebra Technologies Corporation
NASDAQ:ZBRA
|
0.051x |
|
TELECOM ITALIA ADR 1
F:TQIA
|
0.130x |
|
Pinnacle West Capital Corp
NYSE:PNW
|
0.092x |
|
Smurfit Kappa Group PLC
F:SK3
|
0.011x |
Annual Cash Flow Conversion Efficiency for Dr. Reddy’s Laboratories Ltd ADR (2000–2025)
The table below shows the annual cash flow conversion efficiency of Dr. Reddy’s Laboratories Ltd ADR from 2000 to 2025. Review RDY FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $337.17 Billion | $46.43 Billion | 0.138x | -14.97% |
| 2024-03-31 | $280.55 Billion | $45.43 Billion | 0.162x | -36.46% |
| 2023-03-31 | $230.99 Billion | $58.87 Billion | 0.255x | +72.76% |
| 2022-03-31 | $190.53 Billion | $28.11 Billion | 0.148x | -99.02% |
| 2021-03-31 | $2.37 Billion | $35.70 Billion | 15.083x | +3.55% |
| 2020-03-31 | $2.05 Billion | $29.84 Billion | 14.566x | +7014.23% |
| 2019-03-31 | $140.20 Billion | $28.70 Billion | 0.205x | +43.61% |
| 2018-03-31 | $126.46 Billion | $18.03 Billion | 0.143x | -17.80% |
| 2017-03-31 | $124.04 Billion | $21.51 Billion | 0.173x | -46.04% |
| 2016-03-31 | $128.34 Billion | $41.25 Billion | 0.321x | +42.90% |
| 2015-03-31 | $111.30 Billion | $25.03 Billion | 0.225x | +4.93% |
| 2014-03-31 | $90.80 Billion | $19.46 Billion | 0.214x | +1076.68% |
| 2013-03-31 | $731.04 Billion | $13.32 Billion | 0.018x | -93.52% |
| 2012-03-31 | $57.44 Billion | $16.15 Billion | 0.281x | +61.44% |
| 2011-03-31 | $45.99 Billion | $8.01 Billion | 0.174x | -43.49% |
| 2010-03-31 | $42.91 Billion | $13.23 Billion | 0.308x | +187.63% |
| 2009-03-31 | $42.05 Billion | $4.50 Billion | 0.107x | -17.63% |
| 2008-03-31 | $47.07 Billion | $6.12 Billion | 0.130x | -54.17% |
| 2007-03-31 | $41.69 Billion | $11.83 Billion | 0.284x | +283.73% |
| 2006-03-31 | $22.27 Billion | $1.65 Billion | 0.074x | -32.37% |
| 2005-03-31 | $20.95 Billion | $2.29 Billion | 0.109x | -42.46% |
| 2004-03-31 | $21.08 Billion | $4.01 Billion | 0.190x | -18.03% |
| 2003-03-31 | $18.78 Billion | $4.35 Billion | 0.232x | -22.97% |
| 2002-03-31 | $15.44 Billion | $4.65 Billion | 0.301x | +156.40% |
| 2001-03-31 | $5.24 Billion | $614.87 Million | 0.117x | -17.97% |
| 2000-03-31 | $99.87 Million | $14.29 Million | 0.143x | -- |
About Dr. Reddy’s Laboratories Ltd ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more